Imperial College London


Faculty of MedicineDepartment of Immunology and Inflammation

Ken and Mary Minton Chair of Renal Medicine



+44 (0)20 3313 2354f.tam




9N, 15C, Commonwealth BuildingHammersmith HospitalHammersmith Campus





Professor Bruce Riser, Rosalind Franklin University, and CEO BLR Bio, Chicago, IL, USA ; Dr Yao-Chan Lee, National Synchrotron Radiation Research Center, Taiwan; Dr Karen M.C. Yu, Ghong Gung Hospital, Taiwan, International Research Consortium on renal inflammation and fibrosis, 2019

Dr Yao-Chang Lee, National Synchrotron Radiation Research Center, Taiwan, Infrared spectrometry, 2018

Dr Don Williamson, Augusta University Medical Center, IgA nephropathy, 2017

Professor Richard Lafayette, Stanford University, IgA nephropathy, 2017

Professor James Tumlin, GA Nephrology, Georgia, IgA nephropathy, 2017

Professor Felix Knauf, Charité - Universitätsmedizin Berlin, purinergic receptor, inflammasome, 2017

Dr Brad Rovin, The Ohio State University, IgA nephropathy, 2017

Dr Lisa Wilcox, Addenbrookes Hospital, University of Cambridge, IgA nephropathy, 2015

Professor Alexander Rosenkranz, Medical University of Graz, IgA nephropathy, 2015

Professor Volker Vielhauer, Klinikum der Universität München, IgA nephropathy, 2015

Professor Martin Busch, Medical University of Jena, IgA nephropathy, 2015

Professor Donald Fraser, Cardiff University, IgA nephropathy, 2015

Professor Bernd Hohenstein, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, IgA nephropathy, 2015

Dr Danny Gale, Royal Free Hospital, UCL Centre for Nephrology, IgA nephropathy, 2015

Professor Claudia Sommerer, Medical University of Heidelberg, IgA nephropathy, 2015

Professor Gere Sunder-Plassmann, Medical University Vienna, IgA nephropathy, 2015

Dr Mei-Ching Yu, Chang Gung Memorial Hospital at Lin-Kou and Chang Gung University, Infrared spectrometry, renal fibrosis, glomerulonephritis, transplantation, diabetic nephropathy, 2015

Dr Alison Brown, Freeman Hospital, Newcastle upon Tyne, IgA nephropathy, 2015

Dr Chiu-Ching Huang, China Medical University Hospital, IgA nephropathy, 2015

Dr Wu-Chan Yang, Taipei Veterans General Hospital, Division of Nephrology, IgA nephropathy, 2015

Dr Wen-Hung Huang, School of Medicine, Chang Gung University, Chang Gung Memorial Hospital, IgA nephropathy, 2015

Professor Sydney Tang, University of Hong Kong, IgA nephropathy, 2014

Professor Cheuk Chun Szeto, Chinese University of Hong Kong, IgA nephropathy, 2014

Professor Mark Little, Trinity College Dublin, Vasculitis, 2013

Professor Mervyn Singer, University College London, Acute kidney injury, 2013

Professor Peter Rich, University College London, infrared spectrometry, 2011

Professor Matthew Bailey, University of Edinburgh, Purinergic receptors, 2010

Professor Philip Li, Chinese University of Hong Kong, Glomerulonephritis, 2010

Dr Ping-Chin Lai, China Medical University Hospital, IgA nephropathy, Renal transplantation, 2004

Professor Jill Norman, Royal Free Hospital, University College London, 2000

Professor John Feehally, University of Leicester

Prof. Jonathan Barratt, University of Leicester

Dr. Karen Molyneux, University of Leicester

Prof. David Wheeler, Royal Free Hospital, University College London

Dr. Jens G. Leipziger, Aarhus University, Denmark

Dr. Scott Wildman, Medway School of Pharmacy, The Universities of Kent and Greenwich at Medway

Professor Robert Unwin, Royal Free Hospital, University College London

Professor Bruce L Riser, The Chicago Medical School

Dr James Keith Jr., Wyeth/Genetics Institute, Massachuetts.

Guest Lectures

Retroperitoneal fibrosis, East Midland Renal Specialist Registrar Training, online, 2020

Fostamatinib in IgA nephropathy, University of Cambridge, Downing College, Cambridge, UK, 2020

IgA nephropathy and Syk: From laboratory study to clinical trial., Royal Society: international share cost award Taiwan (MOST)-UK Collaborative Workshop:, Chong Gung Hospital, Taiwan, 2019

Chan Woon Cheung Memorial Fund Award Lecture: Spleen tyrosine kinase (Syk): a novel therapeutic target for immune mediated diseases, Hong Kong Society of Nephrology, Hong Kong, 2019

Inflammatory cytokines and fibrotic factors in diabetic nephropathy, Asia Pacific Society of Nephrology/ Hong Kong Society of Nephrology CME course, Hong Kong, 2019

From laboratory to clinical trial: Spleen Tyrosine Kinase (SYK) as a novel therapeutic target in glomerulonephritis and transplant rejection, University of Edinburgh, Edinburgh, 2019

Recurrent Diseases in Transplantation, Fifth International Transplantation Conference, University of Warwick, Coventry, 2019

Clinical trials in IgA nephropathy, The Royal London Hospital, Queen Mary Medical School, London, 2019

Updates in clinical trials in IgA nephropathy, Royal Society of Medicine, London, 2019

Inflammatory cytokines and fibrotic factors in diabetic nephropathy and obesity related kidney disease, Diabetes UK Annual conference, Liverpool, 2019

Tyrsoine kinase inhibition from cell culture to clinical trial, 15th International Symposium on IgA Nephropathy, Buenos Aires, Argentina, 2018

Importance of MCP-1/CCL2 in the diabetic microvascular complications, UCL Institute of Ophthalmology and Moorfield Eye Hospital, London, 2018

Monocyte Chemoattractant Protein-1 (MCP-1) is a Prognostic Biomarker and a Therapeutic Target in Diabetic Nephropathy, International Conference on Biomarker Research in Clinic Medicine, Paris, 2018

From experimental model and cell culture to clinical trial: targeting Spleen Tyrosine Kinase (Syk) in IgA nephropathy, Oxford Kidney Unit, Churchill Hospital, Oxford, 2018

Career Story: The joy and the challenges for a research fellow: from cell culture to clinical trial, Kidney Research UK, Kings College London, 2018

From cell culture to clinical trial: Spleen Tyrosine Kinase (SYK) as a novel therapeutic target in IgA nephropathy, Kidney Research UK Researcher Development Day, Royal Free Hospital, University College London, 2016

Current clinical trial: Treatment of IgA nephropathy with a spleen tyrosine kinase (SYK) inhibitor, 14th International Symposium on IgA Nephropathy, VINCI Congress Center, Tours, France, 2016

Spleen tyrosine kinase in IgA nephropathy, 1st International Congress of Chinese Nephrologists, Scientific Congress on Nephropathies, Hong Kong, China, 2015

Clinical Trials in IgA Nephropathy, The first UK IgA Nephropathy Patient Information Day, National Space Centre, Leicester, 2014

Diabetic nephropathy and obesity related glomerulopathy: inflammatory conditons, 6th Diabetes Conference, Visiongain, London, 2012

Treatment of experimental glomerulonephritis with a Syk inhibitor, Universities of Leicester and Nottingham, East Midland Research Showcase, Loughborough, 2012

In vitro and in vivo models to develop new therapies for renal diseases, ADMET & Predictive Toxicology, Munich, Germany, 2012

Cell culture and in vivo model to develop new treatments for renaldiseases, SMi 6th conference on ADMET, London, 2011

Inflammatory cytokines, profibrotic growth factor biomarkers and therapeutic targets in diabetic nephropathy & obesity-related glomerulopathy, 2nd Annual Diabetes and Diabetic Retinopathy Conference, London, 2011

Cytokines and chemokines as therapeutic targets in renal diseases, BIT 3rd Annual International Congress of Antibodies, Beijing, China, 2011

ATP, P2 receptors, the kidney and inflammation, London rheumatology research club meeting, Royal College of Physicians, London, 2010

Effects of P2X7 Antagonists in Experimental Glomerulonephritis, satellite meeting of American Society of Nephrology, Denver, USA, 2010

Spleen Tyrosine Kinase Inhibitor Reverses Pathological Changes in ExperimentalGlomerulonephritis, 8th Annual Congress of International Drug Discovery Science and Technology, Beijing, China, 2010

Discovery of chemokines mediating fibrotic complications in renal diseases in humans, BIT Life Sciences’ 2nd Annual Protein and Peptide Conference, Seoul, South Korea, 2009

Cytokines and renal progression in diabetic nephropathy, Royal Society of Medicine, London, 2009

P2X7 receptor is a therapeutic target for glomerulonephritis – the effect of gene knockout & receptor antagonist, 7th International Drug Discovery Science and Technology Conference, Shanghai, China, 2009

Treatment of experimental glomerulonephritis with signal transduction inhibitors, Renal Unit, Prince of Wales Hospital, Hong Kong Chinese University Medical School, Hong Kong, China, 2008

A potential role for the ATP-sensitive P2X7 receptor in glomerular injury, Royal Free Hospital/University College Hospital Renal Unit, London, 2006

Chemokines and growth factors in diabetic nephropathy -update and potential for intervention, Royal Society of Medicine, 2005

Urinary chemokines in renal inflammation, Aims of Therapy 2, Emmanuel College, Cambridge, 2004

Cytokine in the pathogenesis and treatment of experimental crescentic glomerulonephritis, 3rd Congress of Nephrology in Internet, 2003

Guy's Hospital: cytokines in glomerulonephritis: from laboratory to the clinic

University of Westminster: cytokines in inflammation: lessons from the Goodpasture’s disease

Research Staff






Research Student Supervision

Blakey,S, Light chain mediated kidney disease

Clarke,C, Rejection of renal allograft

Yap,HL, Diabetic Nephropathy